__
PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.
PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).
PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance.
PWRM’s NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease.
PWRM recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
PWRM has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals.
According to recent estimates, as many as 2.4 million to 4.5 million Americans have Alzheimer’s disease (AD). Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. That’s because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65. (Source: CLICK HERE)
More about PWRM at www.power3medical.com
**************************************************************
CSCO, Cisco Systems, Inc.
CSCO designs, manufactures, and sells Internet Protocol (IP)-based networking and other products to the communications and IT industry worldwide.
** CSCO introduced Collaboration for Events, a new approach to planning, executing and extending the impact of trade shows and conferences. Collaboration for Events provides event planners and executives with customizable options for using collaboration and business video technologies like Web conferencing, telepresence, digital signage and enterprise social software to dramatically expand an event’s reach beyond the physical limitation of an event venue.
With these network-based technologies, organizers can conduct highly interactive physical and virtual events, more effectively measure return on investment, expedite the planning process, and attract the best speakers from around the world, all of which can help raise attendance and revenue.
CSCO’s Collaboration for Events is being introduced at a time when the need for global knowledge exchange is critical, yet travel budgets and corporate spending continue to be scrutinized. In addition, traditional in-person events may find it difficult to make their intended business impact because of a lack of scheduling flexibility and a less-than-optimal, one-size-fits-all approach to diverse attendee interests.
Fortune magazine and ExCel London, a host site for the 2012 Olympic Games, are two customers focused on using collaboration and business video technologies to bring about events of the future.
CSCO has also achieved cost efficiencies by deploying business video and collaboration technologies for its own events, helping the company realize event-related cost savings of more than $100 million to date.
More about CSCO at www.cisco.com
**************************************************************
**************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB).
